ECYT: Endocyte, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 3, 6:51 AM Endocyte (ECYT): Q1 EPS of -$0.11 misses by $0.05. Revenue of $14.5M beats by $0.26M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, March 27, 12:54 PM Midday top 10 gainers: CHCI +45%. RVLT +35%. UEPS +24%. LIVE +20%. UTSI +20%. ECYT +11%. MFRM +10%. STSI +10%. PGTI +10%. GSL +10%.
Midday top 10 losers: ASTM -38%. EVBS -23%. ISNS -19%. ATOS -14%. CLF -15%. BAA -13%. GV -12%. LOGM -11%. MBLX -11%. LEDS -10%. Comment! [On the Move]
Wednesday, March 27, 9:19 AM Wedbush ups Endocyte (ECYT) price target to $20 from $16 citing future cash flows from potential cancer drug Vintafolide which is pending approval in Europe. Baird upgraded the stock earlier in the week with similar comments. Shares +1.9% premarket. 1 Comment [Healthcare]
Monday, March 25, 10:04 AM Endocyte (ECYT +6.1%) ramps higher after Baird upgrades the stock to Outperform with a $13 price target and says the company's chemo drug Vintafolide should be a "catalyst" going forward. Comment! [Healthcare]
Monday, February 25, 4:51 PM Endocyte (ECYT): Q4 EPS of -$0.02 in-line. Revenue of $14.5M beats by $0.9M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, February 15, 11:32 AM Endocyte (ECYT +3.9%) moves higher today after Roth Capital Partners have initiated coverage of biopharmaceutical firm with a Buy rating and a $15 price target. Comment! [On the Move, Healthcare]
Tuesday, January 15, 1:49 PM Endocyte (ECYT +3.2%) gets an upside bump from an intitation at Credit Suisse with an Outperform rating and and a price target of $16. The firm thinks the stock should see significant appreciation ahead of some key catalysts in early 2014, including a potential EU approval, pivotal Phase III data in ovarian cancer, and robust Phase II data in lung cancer. Those drivers, plus a deep-pocket partner in Merck, make for a favorable risk/reward profile. Comment! [Healthcare, On the Move]
Friday, November 2, 2012, 12:45 PM Midday top 10 gainers: BGFV +38%. ALC +22%. HGG +21%. QTM +20%. DNDN +20%. TRIP +19%. TPC +19%. DGLY +17%. AVNW +17%. JOE +16%.
Midday top 10 Losers: ACTV -45%. GLUU -17%. NTS -15%. GMED -15%. AXTI -14%. ECYT -14%. BCOR -13%. PBI -13%. SWKS -13%. VRTX -13%. Comment! [On the Move]
Thursday, September 27, 2012, 9:51 AM The EU grants orphan drug status to Endocyte's (ECYT +2.1%) folic acid solution for helping to treat ovarian cancer. The solution is used as a pre-injection for the radiodiagnostic imaging agent, etarfolatide, to help select patients who can be treated with Endocyte's vintafolide drug, which it's developing with Merck and which is in Phase II and III cancer trials. (PR) Comment! [Healthcare]
Tuesday, April 17, 2012, 3:28 PM Endocyte (ECYT +9.7%) extends a second day of gains after RBC Capital raised its price target to $12 from $8 earlier today, saying it continues to view the stock as a "compelling investment." RBC sees several upcoming catalysts for the stock, including the resumption of Doxil supply in Q4 and an agreement with the FDA on a Phase III statistical plan in Q3. Comment! [Healthcare, On the Move]
Tuesday, April 17, 2012, 9:00 AM Premarket gainers: PSTI +7%. LNG +7%. CPST +6%. CMA +6%. CTIC +6%. FSLR +5%. TSL +5%. ECYT +5%. ING +4%. GMXR +4%. BCS +3%. DB +3%. VLO +3%.
Losers: CHOP -17%. AMTG -6%. STWD -3%. Comment! [On the Move]
Monday, April 16, 2012, 9:05 AM Premarket gainers: ECYT +114%. DRJ +30%. CSIQ +9%. SQNM +9%. LDK +7%. TSL +6%. RENN +4%. YGE +4%. STX +4%. JASO +4%. STP +4%. ANR +3%.
Losers: PCO -47%. HALO -22%. SANG -5%. BAX -4%. MAT -4%. RBS -3%. VALE -3%. Comment! [On the Move]
Monday, April 16, 2012, 8:22 AM Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M upfront plus milestone payouts of up to $880M to develop and market experimental cancer drug vintafolide, which is being evaluated in a Phase 3 clinical trial for ovarian cancer and a Phase 2 trial for non-small cell lung cancer. (PR) Comment! [Healthcare, On the Move]
Wednesday, March 14, 2012, 11:35 AM Endocyte (ECYT +37.4%) shares skyrocket after the biopharma company says it will submit conditional marketing authorization applications for its EC145 and EC20 ovarian cancer treatments in Europe after meeting with EU health authorities. Comment! [Healthcare, On the Move]
Wednesday, December 14, 2011, 9:00 AM Premarket gainers: NBG +10%. AVP +8%. BRCM +7%. CPST +5%. MTL +3%.
Losers: FSLR -12%. LNG -7%. TSL -6%. GMCR -5%. GRFS -3%. ECYT -3%. Comment! [On the Move]
Tuesday, December 13, 2011, 10:20 AM It's a bloodbath for shares of Endocyte (ECYT -61%) after analysis of trials on its Precedent cancer treatment tips off that early conditional approval in the EU appears less certain now. Baird downgrades the company to Neutral, saying "stepping to the sidelines for now makes the most sense." 1 Comment [On the Move, Healthcare]

ECYT Endocyte, Inc.

ECYT

Endocyte, Inc.